# Spruce Medimaging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spruce-medimaging

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.medspruce.com
- Latest round: Series A (Aug 8, 2024)
- Investors on record: 2

## About

Founded in 2022 and based in Beijing, China, Spruce Medimaging operates as a medical company that focuses on providing clinical medicine evaluation services. It acquired ISO-13485 quality management system certification and ISO-27001 quality management system certification. The company cooperated with Yizhong Pharma, Ausun Pharm, Fosun Pharma, and other enterprises. In August 2024, Spruce Medimaging closed a series A funding.

The company is mainly engaged in independent imaging evaluation (IRC) services for innovative drug clinical research centers. The business covers medical imaging evaluation, clinical medicine evaluation, and eligibility evaluation of clinical research subjects for doctors and pharmaceutical companies. Its image types include CT, MRI, and X-Ray, which adopt technical platforms such as medical imaging, clinical data, and medical AI. The target customers of the company are medical institutions, biopharmaceutical companies, and medical device companies.

The company generates revenue by providing clinical medicine evaluation and related services.

The company will use the series A funding to upgrade SPRUCE medical imaging assessment systems, improve the international standard system, recruit teams, expand the application areas of independent imaging IRC, and expand the market.

## Funding rounds

- Series A, Aug 8, 2024 — Ken Capital, Taikun Fund

## Investors

- Ken Capital (https://capitalatlas.ai/funds/ken-capital) — Series A
- Taikun Fund — Series A